Belumosudil with ruxolitinib for chronic graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of two medications (belumosudil and ruxolitinib) for people with chronic graft-versus-host disease (cGvHD) that has not improved with steroid treatment. The goal is to see if this combination can better control the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe cGvHD, or mild cGvHD with certain high-risk features (like low platelet counts).
- Your cGvHD has not responded to first-line steroid therapy, as defined in the study.
- You are currently taking a low dose of steroids (less than 0.5 mg/kg/day of prednisone or equivalent).
- You have adequate blood counts and liver/kidney function, as confirmed by recent tests.
- You are not currently taking ruxolitinib for acute GvHD, and you have not taken a JAK inhibitor or ROCK2 inhibitor within the past 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medications, belumosudil and ruxolitinib, to see which one works better for a type of graft-versus-host disease (GVHD) that affects the liver after a stem cell transplant. GVHD happens when donor cells attack the patient's body, and this study focuses on patients whose liver GVHD has not improved with steroids or has gotten worse. The study aims to find a more effective treatment to control this condition.
This trial tests a new combination of two drugs (an IL6-receptor inhibitor plus belumosudil) for people with chronic graft-versus-host disease that hasn't improved with belumosudil alone. It aims to see if this combination is safe and helpful for controlling cGVHD symptoms.
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medicine called belumosudil for people who have chronic graft-versus-host disease (cGVHD) that has not improved with at least two earlier treatments. It compares belumosudil to other available treatments to see which works better and is safer.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hear when a new cGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.